Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Core Insights - Inhibrx Biosciences, Inc. announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for advanced or metastatic, unresectable colorectal adenocarcinoma [1][2] Efficacy Data - Efficacy was assessed in 10 of the 13 patients, showing one complete response (CR), three partial responses (PR), and six cases of stable disease (SD) [2] - Durable disease control lasting ≥180 days was observed in 46.2% of patients, with a median progression-free survival (PFS) of 7.85 months [2] - All patients had received at least one prior line of systemic therapy, with a median of two prior therapies [2] Safety Data - Ozekibart-related treatment-emergent adverse events (TEAEs) were reported in 84.6% of patients, with most being grade 1 or 2 [3] - Grade ≥3 TEAEs were observed in 30.8% of patients, with common TEAEs including nausea, increased alanine aminotransferase, diarrhea, and fatigue [3] Future Plans - Inhibrx has initiated a new expansion cohort to validate findings in a more uniform patient population, expecting to enroll up to 50 patients [4] - Data from this expansion cohort are anticipated in Q3 2025 [4] Company Overview - Inhibrx is a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases [1] - The company utilizes diverse methods of protein engineering to address complex target and disease biology [9]